Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Atrial Natriuretic Peptide (ANP)
ANH; ANF; CDD; Atrial Natriuretic Factor; Atrial Natriuretic Hormone; Atriopeptin; Cardionatrine; Cardiodilatin
- Product No.CEA225Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodCompetitive Inhibition
- Assay Length2h
- Detection Range12.35-1,000pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 5.23pg/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 479
For more details, please contact local distributors! US$ 684 US$ 3078 US$ 5814 US$ 47880
Specificity
This assay has high sensitivity and excellent specificity for detection of Atrial Natriuretic Peptide (ANP).
No significant cross-reactivity or interference between Atrial Natriuretic Peptide (ANP) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Atrial Natriuretic Peptide (ANP) and the recovery rates were calculated by comparing the measured value to the expected amount of Atrial Natriuretic Peptide (ANP) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 90-102 | 98 |
EDTA plasma(n=5) | 80-104 | 101 |
heparin plasma(n=5) | 98-105 | 102 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Atrial Natriuretic Peptide (ANP) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Atrial Natriuretic Peptide (ANP) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Atrial Natriuretic Peptide (ANP) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 96-105% | 86-102% | 88-103% | 79-97% |
EDTA plasma(n=5) | 94-105% | 80-91% | 80-95% | 91-98% |
heparin plasma(n=5) | 87-94% | 78-93% | 98-105% | 89-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
And then add 50µL prepared Detection Reagent A immediately.
Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
8 | Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function PubMed: 21616283 |
Basic Research in Cardiology | Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery PubMed: 21769675 |
Neuropsychobiology. | Atrial natriuretic Peptide, arginine vasopressin Peptide and cortisol serum levels in opiate-dependent patients PubMed: 23406607 |
European addiction research | Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment. Pubmed: 24356727 |
Crit Care. | Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx Pubmed:25497357 |
Diabet Med. | Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes. Pubmed:26927445 |
J Ethnopharmacol | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by reCavia (Guinea pig )lating p38 and NF-κb pathway Pubmed:26970569 |
Journal of Babylon University/Pure and Applied Sciences | Blood Pressure and Atrial Natriuretic Peptide (ANP) Levels in Patients with Autosomal Dominant Polycystic Kidney Disease. papers:uobj_paper_2016_62613672.pdf |
PLoS One | Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy pubmed:29240788 |
Drug Delivery | Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy. pubmed:29063791 |
Elife | SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation Pubmed:29504933 |
Science of the Total Environment | Co-exposure of silica nanoparticles and methylmercury induced cardiac toxicity and Pubmed:29727991 |
The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice Pubmed:29929978 |
Pediatric Cardiology | Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease Pubmed:29392348 |
FASEB Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure Pubmed: 30230922 |
Endokrynologia Polska | Endothelin-1 (ET-1), N-terminal fragment of proatrial natriuretic peptide (NTpro-ANP) and tumor necrosis factor alpha (TNF-α) in children with primary hypertension … Pubmed: 30359461 |
International Journal of Peptide Research and Therapeutics | ANP/NPRA Inhibits Epithelial-Mesenchymal Transition of Airway by Targeting Smad3 in Asthma |
Van Veterinary Journal | Relationship between Natriuretic Peptide Levels with Heart and Kidney Parameters in Rats with Chronic Renal Failure. |
Acta Pharmaceutica Sinica B | The poly (ADP-ribosyl) ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy 34094834 |
Peptides | Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy 34624429 |
Peptides | Osteocrin alleviates cardiac hypertrophy via attenuating oxidative stress Pubmed:35218795 |